Q32 Bio concludes merger deal with Homology Medicines
Clinical stage biotechnology company Q32 Bio has announced the conclusion of its merger with Homology Medicines, for an undisclosed sum.
Clinical stage biotechnology company Q32 Bio has announced the conclusion of its merger with Homology Medicines, for an undisclosed sum.
AOB Pharma has signed an exclusive license and development agreement with Maruho for the development and marketing of its topical biologic, B244, for inflammatory indications in Japan.
Novartis subsidiary Sandoz has made available a citrate-free, high-concentration formulation (HCF) of Hyrimoz (adalimumab-adaz) injection, a biosimilar of Humira (adalimumab), in the United States (US).
Rani Therapeutics has expanded its collaboration with Celltrion for developing RT-105, an orally administered adalimumab biosimilar.
Graybug Vision and CalciMedica have signed a definitive merger agreement to create a new clinical-stage biopharmaceutical company.
Galapagos has obtained marketing authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Jyseleca (filgotinib 200mg tablets) to treat ulcerative colitis (UC) in Great Britain.
The US Department of Defense (DOD) has approved the funding of US-based private pharmaceutical firm Humanetics to test its drug candidate BIO 300 in treating pulmonary inflammation triggered by COVID-19.